Mark E. Robinson

15 papers receiving 234 citations

Peers

Mark E. Robinson
Comparison fields: 5 of 47
  • Immunology 81
  • Physiology 61
  • Epidemiology 79
  • Hematology 21
  • Cancer Research 22
Replace Sandra Rodríguez-López with:
Sandra Rodríguez-López United States
Marc Stahel Switzerland
Sandra Schmidhofer Germany
Katarzyna Parzych United Kingdom
Kristine M. Morin United States
Chloé Paul France
Michael Eberhardson Sweden
Makandjou-Ola Eusebio Poland
Alexander Garcia United States
Mark E. Robinson relative to Sandra Rodríguez-López United States Sandra Rodríguez-López's profile →
Citations per field
00.5×6.6×
Sandra Rodríguez-López · 1×
Citations per year

Countries citing papers authored by Mark E. Robinson

Since Specialization
Citations

This map shows the geographic impact of Mark E. Robinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Robinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Robinson more than expected).

Fields of papers citing papers by Mark E. Robinson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Robinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Robinson. The network helps show where Mark E. Robinson may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark E. Robinson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark E. Robinson Line = papers co-authored together Mark E. Robinson links everyone, so they are left out of the graph.

All Works

17 of 17 papers shown
#Work
1 2018116
2 201933
3 202128
4 202113
5 201713
6 202013
7 20195
8 20234
9 20243
10 20242
11 20252
12 20241
13 20211
14 20221
15 20211
16 20240
17 20250

About Mark E. Robinson

Mark E. Robinson is a scholar working on Hematology, Genetics, Physiology, Cancer Research and Neurology, having authored 17 papers that have together received 236 indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (4 papers), Chronic Myeloid Leukemia Treatments (3 papers), Cancer, Lipids, and Metabolism (2 papers), Acute Myeloid Leukemia Research (2 papers), Genomics and Chromatin Dynamics (2 papers), Ferroptosis and cancer prognosis (2 papers), Immune Cell Function and Interaction (2 papers) and Vascular Malformations Diagnosis and Treatment (2 papers). The work is most often cited by research in Immunology (81 citations), Physiology (61 citations), Epidemiology (79 citations), Hematology (21 citations) and Cancer Research (22 citations). Mark E. Robinson has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Niklas Feldhahn, Leandro Castellano, Federica M. Marelli‐Berg, Jakob Loschko, Valeria Scagliotti, Carles Gaston‐Massuet, Elizabeth G. Wood, Mathieu-Benoı̂t Voisin, Marika Charalambous and M. Paula Longhi. Their work appears in journals such as Blood, Proceedings of the National Academy of Sciences, iScience, Science Translational Medicine and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026